the australian- spec buy. , page-2

Direct from the article "But that's not exactly why Mathieson has tipped in $1 million for a 15 per cent stake at 6c a pop in iSonea, which is honing its asthma-management tool into a smartphone app to detect and manage an ailment that afflicts 300 million people globally.
Mathieson, who has dabbled in resource plays and the generic drug maker Mayne Pharma, believes such early-stage healthcare plays suits his risk-reward equation. "The first criteria is I don't like to lose money," he says. "There's no use making 10-15 per cent. I would rather go in when there's big multiples to be made."